Approval · Notice of Compliance 28315 · 2022
ORLADEYO: Notice of Compliance 28315
Issued June 2, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28315
- Date
- June 2, 2022
- Company
- Biocryst Pharmaceuticals IncDurham, North Carolina, United States
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ORLADEYO | 02527693 | Marketed |
Medicinal ingredients
- BEROTRALSTAT HYDROCHLORIDE 150 MG per CAP